1887

Abstract

Penicillin has been the mainstay of treatment for meningococcal disease. Isolates of that are less susceptible to penicillin have been reported in several countries and in recent years have become more common. The clinical significance of this reduced susceptibility has not been investigated on a large scale. Hence, isolates from culture-confirmed cases of meningococcal disease in England and Wales, between 1993 and 2000, were routinely serogrouped, serotyped and tested for susceptibility to penicillin. These data were linked to death registrations and analysed retrospectively. The changing trends in susceptibility were described and multivariate logistic regression was used to examine associations between strain characteristics and fatal outcome. The frequency of isolates less susceptible to penicillin increased from <6% in 1993 to >18% in 2000. In particular, isolates expressing serogroup C with serotype 2b and serogroup W135 had a higher frequency of reduced penicillin susceptibility (49% and 55%, respectively). There was no evidence of an association between fatal outcome and infection with a less penicillin-susceptible isolate. Fatal outcome was associated with serogroup and serotype, with the odds of death for cases infected with C:2a and B:2a strains three-fold higher when compared with the baseline. For this large dataset the serogroup and serotype of the infecting strain influenced mortality from meningococcal disease and may be markers for hypervirulence. No association was found between reduced penicillin susceptibility and fatal outcome, but the increasing frequency of isolates less susceptible to penicillin highlights the need for continued surveillance.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/0022-1317-51-10-855
2002-10-01
2024-04-18
Loading full text...

Full text loading...

/deliver/fulltext/jmm/51/10/855.html?itemId=/content/journal/jmm/10.1099/0022-1317-51-10-855&mimeType=html&fmt=ahah

References

  1. Sutcliffe EM, Jones DM, El-Sheikh S, Percival A. Penicillin-insensitive meningococci in the UK. Lancet 1988; i:657–658
    [Google Scholar]
  2. Botha P. Penicillin-resistant Neisseria meningitidis in Southern Africa. Lancet 1988; i:54
    [Google Scholar]
  3. Sáez-Nieto JA, Campos J. Penicillin-resistant strains of Neisseria meningitidis in Spain. Lancet 1988; i:1452–1453
    [Google Scholar]
  4. Jackson LA, Tenover FC, Baker C. et al. Prevalence of Neisseria meningitidis relatively resistant to penicillin in the United States, 1991. J Infect Dis 1994; 169:438–441 [CrossRef]
    [Google Scholar]
  5. Saez-Nieto JA, Vazquez JA, Marcos C. Meningococci moderately resistant to penicillin. Lancet 1990; 336:54
    [Google Scholar]
  6. The Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme 2000. Commun Dis Intell 2001; 25:113–121
    [Google Scholar]
  7. Kaczmarksi EB, Sutcliffe E, Mallard RH. Antibiotic susceptibility data and trends for clinical isolates of Neisseria meningitidis : 1984–1994. J Infect 1996; 32:91–92
    [Google Scholar]
  8. Kaczmarski EB. Meningococcal disease in England and Wales: 1995. Commun Dis Rep CDR Rev 1997; 7:R55–R59
    [Google Scholar]
  9. Turner PC, Southern KW, Spencer NJB, Pullen H. Treatment failure in meningococcal meningitis. Lancet 1990; 335:732–733
    [Google Scholar]
  10. Bardi L, Badolati A, Corso A, Rossi MA. [Failure of the treatment with penicillin in a case of Neisseria meningitidis meningitis.]. Medicina (B Aires) 1994; 54:427–430
    [Google Scholar]
  11. Luaces Cubells C, Garcia Garcia JJ, Roca Martinez J, Latorre Otin CL. Clinical data in children with meningococcal meningitis in a Spanish hospital. Acta Paediatr 1997; 86:26–29 [CrossRef]
    [Google Scholar]
  12. Iversen B, Aavitsland P. Meningococcal disease in Norway 1992–1995.Epidemiology and fatality. Scand J Infect Dis 1996; 28:253–259 [CrossRef]
    [Google Scholar]
  13. Scholten RJPM, Bijlmer HA, Valkenburg HA, Dankert J. Patient and strain characteristics in relation to the outcome of meningococcal disease: a multivariate analysis. Epidemiol Infect 1994; 112:115–124 [CrossRef]
    [Google Scholar]
  14. Spanjaard L, Bol P, de Marie S, Zanen HC. Association of meningococcal serotypes with the course of disease: serotypes 2a and 2b in the Netherlands, 1959–1981. J Infect Dis 1987; 155:277–282 [CrossRef]
    [Google Scholar]
  15. Booy R, Habibi P, Nadel S. et al. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch Dis Child 2001; 85:386–390 [CrossRef]
    [Google Scholar]
  16. Thorburn K, Baines P, Thomson A, Hart CA. Mortality in severe meningococcal disease. Arch Dis Child 2001; 85:382–385 [CrossRef]
    [Google Scholar]
  17. Brassier N, Lepoutre A, Guibourdenche M, Moyse C, Riou JY. Meningococcal meningitis and meningococcemia: epidemiological study, France (1985–1991). Med Mal Infect 1995; 25:584–592 [CrossRef]
    [Google Scholar]
  18. Ward J, Hanna JN, Bates JR., Selvey LA. Enhanced surveillance for meningococcal disease in Queensland in 1999. Commun Dis Intell 2000; 24:332–335
    [Google Scholar]
  19. Cartwright K, Reilly S, White D, Stuart J. Early treatment with parenteral penicillin in meningococcal disease. BMJ 1992; 305:143–147 [CrossRef]
    [Google Scholar]
  20. Feavers IM, Fox AJ, Gray S, Jones DM, Maiden MC. Antigenic diversity of meningococcal outer membrane protein PorA has implications for epidemiological analysis and vaccine design. Clin Diagn Lab Immunol 1996; 3:444–450
    [Google Scholar]
  21. Tapsall JW, Shultz T, Limnios E. et al. Surveillance of antibiotic resistance in invasive isolates of Neisseria meningitidis in Australia 1994–1999.National Neisseria Network of Australia. Pathology 2001; 33:359–361
    [Google Scholar]
  22. Brown S, Riley G, Jamieson F. Neisseria meningitidis with decreased susceptibility to penicillin in Ontario, Canada 1997–2000. Can Commun Dis Rep 2001; 27:73–75
    [Google Scholar]
  23. Berrón S, Vázquez JA. Increase in moderate penicillin resistance and serogroup C in meningococcal strains isolated in Spain.Is there any relationship? Clin Infect Dis ; 1994; 18161–165 [CrossRef]
  24. Ashton FE, Ryan JA, Borczyk A, Caugant DA, Mancino L, Huang D. Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J Clin Microbiol 1991; 29:2489–2493
    [Google Scholar]
  25. Kaczmarski EB, Ragunathan PL, Marsh J, Gray SJ, Guiver M. Creating a national service for the diagnosis of meningococcal disease by polymerase chain reaction. Commun Dis Public Health 1998; 1:54–56
    [Google Scholar]
  26. Hieber JP, Nelson JD. A pharmacologic evaluation of penicillin in children with purulent meningitis. N Engl J Med 1977; 297:410–413 [CrossRef]
    [Google Scholar]
  27. Antignac A, Kriz P, Tzanakaki G, Alonso J-M, Taha M-K. Polymorphism of Neisseria meningitidis penA gene associated with reduced susceptibility to penicillin. J Antimicrob Chemother 2001; 47:285–296 [CrossRef]
    [Google Scholar]
  28. Maiden MCJ, Bygraves JA, Feil E. et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 1998; 95:3140–3145 [CrossRef]
    [Google Scholar]
  29. Donaldson L, Moores Y, Howe J. Chief Medical Officer, Chief nursing officer, Chief pharmacist. Introduction of immunisation against group C meningococcal infection. Department of Health 1999 Available from www.doh.gov.uk/cmo/cmo9902.htm (March 02
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/0022-1317-51-10-855
Loading
/content/journal/jmm/10.1099/0022-1317-51-10-855
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error